To boost early detection of lung cancer in India
Johnson & Johnson MedTech has onboarded Qure.ai as a strategic partner with Johnson & Johnson, a Johnson & Johnson company, to enhance early detection of lung cancer in India. The collaboration brings together cutting-edge AI and medical technology, helping identify lung cancer at its most treatable stage.
The initiative is part of Project BreatheEZ, a broader strategic collaboration between Qure.ai and Johnson & Johnson MedTech, and designed to establish AI-led Incidental Pulmonary Nodule (IPN) Detection clinics across leading hospitals in India. These clinics will act as integrated screening hubs, optimising early detection, triaging, and follow-up care for lung cancer patients. As part of this collaboration, Qure.ai’s AI technology will be deployed across 10 hub medical centres in India, with an additional 20 supporting spoke sites. The first such clinic has been launched in Thangam Cancer Centre in Namakkal, Tamil Nadu.
Anuj Virmani, MD, India, Johnson & Johnson MedTech, said, “Our collaboration with Qure.ai is a testament to our commitment to advancing healthcare through innovative solutions continues to drive impactful collaborations and integrating our solutions in lung cancer.”
